Logo image of SNSE

SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Fundamental Analysis

USA - NASDAQ:SNSE - US81728A2078 - Common Stock

8.9 USD
-0.12 (-1.36%)
Last: 9/16/2025, 8:00:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SNSE. SNSE was compared to 540 industry peers in the Biotechnology industry. The financial health of SNSE is average, but there are quite some concerns on its profitability. SNSE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SNSE has reported negative net income.
SNSE had a negative operating cash flow in the past year.
In the past 5 years SNSE always reported negative net income.
SNSE had a negative operating cash flow in each of the past 5 years.
SNSE Yearly Net Income VS EBIT VS OCF VS FCFSNSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

SNSE has a Return On Assets of -84.39%. This is in the lower half of the industry: SNSE underperforms 70.93% of its industry peers.
Looking at the Return On Equity, with a value of -98.20%, SNSE is in line with its industry, outperforming 46.11% of the companies in the same industry.
Industry RankSector Rank
ROA -84.39%
ROE -98.2%
ROIC N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
SNSE Yearly ROA, ROE, ROICSNSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNSE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNSE Yearly Profit, Operating, Gross MarginsSNSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for SNSE has been increased compared to 1 year ago.
The number of shares outstanding for SNSE has been reduced compared to 5 years ago.
The debt/assets ratio for SNSE has been reduced compared to a year ago.
SNSE Yearly Shares OutstandingSNSE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SNSE Yearly Total Debt VS Total AssetsSNSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -12.46, we must say that SNSE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -12.46, SNSE is not doing good in the industry: 76.85% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that SNSE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, SNSE is in line with its industry, outperforming 50.37% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.46
ROIC/WACCN/A
WACCN/A
SNSE Yearly LT Debt VS Equity VS FCFSNSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

SNSE has a Current Ratio of 7.64. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.64, SNSE is doing good in the industry, outperforming 71.67% of the companies in the same industry.
A Quick Ratio of 7.64 indicates that SNSE has no problem at all paying its short term obligations.
The Quick ratio of SNSE (7.64) is better than 72.04% of its industry peers.
Industry RankSector Rank
Current Ratio 7.64
Quick Ratio 7.64
SNSE Yearly Current Assets VS Current LiabilitesSNSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

SNSE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.70%, which is quite good.
EPS 1Y (TTM)9.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.36% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.79%
EPS Next 2Y24.29%
EPS Next 3Y12.13%
EPS Next 5Y8.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNSE Yearly Revenue VS EstimatesSNSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M
SNSE Yearly EPS VS EstimatesSNSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNSE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNSE Price Earnings VS Forward Price EarningsSNSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNSE Per share dataSNSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

SNSE's earnings are expected to grow with 12.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.29%
EPS Next 3Y12.13%

More info and screens

0

5. Dividend

5.1 Amount

SNSE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSEI BIOTHERAPEUTICS INC

NASDAQ:SNSE (9/16/2025, 8:00:02 PM)

8.9

-0.12 (-1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners7.69%
Inst Owner Change-95.39%
Ins Owners2.11%
Ins Owner Change0%
Market Cap11.21M
Analysts86.67
Price Target33.15 (272.47%)
Short Float %1.24%
Short Ratio0.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.51%
Min EPS beat(2)-18.53%
Max EPS beat(2)31.55%
EPS beat(4)2
Avg EPS beat(4)3.05%
Min EPS beat(4)-18.53%
Max EPS beat(4)31.55%
EPS beat(8)5
Avg EPS beat(8)3.3%
EPS beat(12)8
Avg EPS beat(12)2.41%
EPS beat(16)10
Avg EPS beat(16)1.04%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-51.85%
PT rev (3m)712.5%
EPS NQ rev (1m)25.05%
EPS NQ rev (3m)-1230.36%
EPS NY rev (1m)5.75%
EPS NY rev (3m)-1986.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-21.31
EYN/A
EPS(NY)-10.92
Fwd EYN/A
FCF(TTM)-19.27
FCFYN/A
OCF(TTM)-19.26
OCFYN/A
SpS0
BVpS21.68
TBVpS21.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.39%
ROE -98.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.64
Quick Ratio 7.64
Altman-Z -12.46
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.02%
Cap/Depr(5y)183.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.18%
EPS Next Y14.79%
EPS Next 2Y24.29%
EPS Next 3Y12.13%
EPS Next 5Y8.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.91%
EBIT Next 3Y-12.07%
EBIT Next 5YN/A
FCF growth 1Y36.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.43%
OCF growth 3YN/A
OCF growth 5YN/A